On April 28, 2026, Erasca disclosed phase 1 data for its pan-RAS molecular glue ERAS-0015 that included a grade 5 pneumonitis event in a pancreatic cancer patient who withdrew supportive care and died, alongside Revolution Medicines issuing allegations of patent infringement and trade secret misappropriation related to the drug. Erasca shares plunged nearly 48% the next trading day. Tango has an active clinical collaboration and supply agreement with Erasca to evaluate vopimetostat (its PRMT5 inhibitor, also referred to as TNG-462) in combination with ERAS-0015 in MTAP-deleted, RAS-mutant cancers including pancreatic cancer. This news raised immediate concerns about risks to the partnered program, prompting profit-taking in TNGX after its recent sharp run-up to all-time highs on its own positive clinical momentum. Volume surged above average with no direct company-specific negative update from Tango itself (Q1 earnings not due until May 11).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.